ES2570461T3 - Mejora en la promoción del crecimiento compensatorio sano - Google Patents

Mejora en la promoción del crecimiento compensatorio sano

Info

Publication number
ES2570461T3
ES2570461T3 ES10710358T ES10710358T ES2570461T3 ES 2570461 T3 ES2570461 T3 ES 2570461T3 ES 10710358 T ES10710358 T ES 10710358T ES 10710358 T ES10710358 T ES 10710358T ES 2570461 T3 ES2570461 T3 ES 2570461T3
Authority
ES
Spain
Prior art keywords
period
promotion
healthy
improvement
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10710358T
Other languages
English (en)
Other versions
ES2570461T5 (es
Inventor
Olivier Aprikian
Florence Blancher
Catherine Mace
Yassaman Shahkhalili
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40802132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2570461(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec SA filed Critical Nestec SA
Application granted granted Critical
Publication of ES2570461T3 publication Critical patent/ES2570461T3/es
Publication of ES2570461T5 publication Critical patent/ES2570461T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de una fuente proteica que lleva proteínas de caseína en la preparación de una composición nutricional para un bebé o un niño pequeño que atraviesa un periodo de crecimiento compensatorio después de un periodo de restricción del crecimiento, durante o tras dicho periodo de crecimiento compensatorio, a fin de reducir el riesgo de desarrollar resistencia a la insulina o diabetes de tipo 2 en la vida posterior del bebé o un niño pequeño.
ES10710358T 2009-04-03 2010-03-26 Mejora en la promoción del crecimiento compensatorio sano Active ES2570461T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09157244 2009-04-03
PCT/EP2010/054032 WO2010112430A1 (en) 2009-04-03 2010-03-26 Improvement in promotion of healthy catch-up growth

Publications (2)

Publication Number Publication Date
ES2570461T3 true ES2570461T3 (es) 2016-05-18
ES2570461T5 ES2570461T5 (es) 2020-04-03

Family

ID=40802132

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10710358T Active ES2570461T5 (es) 2009-04-03 2010-03-26 Mejora en la promoción del crecimiento compensatorio sano

Country Status (15)

Country Link
US (1) US8846612B2 (es)
EP (1) EP2413952B2 (es)
CN (1) CN102378632A (es)
AU (1) AU2010230283B2 (es)
BR (1) BRPI1014065A2 (es)
CA (1) CA2755860A1 (es)
CL (1) CL2011002465A1 (es)
ES (1) ES2570461T5 (es)
MX (1) MX2011010454A (es)
MY (1) MY183275A (es)
PL (1) PL2413952T3 (es)
RU (1) RU2011144581A (es)
SG (1) SG174355A1 (es)
TW (1) TW201039754A (es)
WO (1) WO2010112430A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2514435A1 (en) * 2011-04-19 2012-10-24 Nestec S.A. Infant formula for use in the prevention of cardiovascular diseases
DK2734049T3 (en) 2011-06-20 2018-07-30 Heinz Co Brands H J Llc PROBIOTIC COMPOSITIONS AND PROCEDURES
EP3718410A1 (en) * 2012-03-12 2020-10-07 N.V. Nutricia Process for the humanization of animal skim milk and products obtained thereby
SE1251123A1 (sv) * 2012-10-05 2014-04-06 Indevex Ab Publ Födoämnesprodukt
PL2994150T3 (pl) 2013-05-10 2019-09-30 H.J. Heinz Company Brands Llc Probiotyki i sposoby zastosowania
WO2015041515A1 (en) 2013-09-19 2015-03-26 N.V. Nutricia Improved process for the humanization of animal skim milk
MX381155B (es) * 2013-11-29 2025-03-12 Soc Des Produits Nestle S A Star Composiciones nutritivas adaptadas a la edad con un contenido de proteína variable.
WO2015078974A1 (en) * 2013-11-29 2015-06-04 Nestec S.A. Infant nutrition for improvement in insulin sensitivity later in life
PL3145334T3 (pl) * 2014-05-19 2020-06-01 N.V. Nutricia Formulacje dojelitowe dla przedwcześnie urodzonych niemowląt zawierające zoptymalizowane poziomy przyjmowania fenyloalaniny
EP3145333B1 (en) * 2014-05-19 2020-11-04 N.V. Nutricia Infant formula with optimised amino acid profiles
US10251913B2 (en) 2014-11-19 2019-04-09 Nestec S.A. Use of whey protein micelles and polysaccharides for improving insulin profile
LT3297653T (lt) 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
EP3302104B1 (en) * 2015-06-04 2020-09-30 Balchem Corporation Hydration control for choline salts
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
LT3541366T (lt) 2016-11-21 2025-03-10 Amylyx Pharmaceuticals, Inc. Eksendino (9-39) buferiniai preparatai
EP3582637A1 (en) 2017-02-20 2019-12-25 Société des Produits Nestlé S.A. Nutritional compositions with partially hydrolysed proteins for use in inducing glucose and/or insulin response(s) close to the ones observed with human milk
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
EP4190324A4 (en) * 2020-07-31 2024-08-14 Otsuka Pharmaceutical Factory, Inc. NUTRITION FORMULATION
US20250302082A1 (en) * 2022-07-29 2025-10-02 Abbott Laboratories Methods for promoting healthy catch-up-growth
CN117158379B (zh) * 2023-09-27 2026-04-17 安徽医科大学 一种小鼠孕期宫内生长受限模型及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1092938C (zh) 1996-04-12 2002-10-23 贝斯以色列护理医疗中心有限公司 用于糖尿病患者的补充食品条
AUPO272196A0 (en) * 1996-10-02 1996-10-24 Horton, David Robert Filtration apparatus
EP0880902A1 (fr) 1997-05-27 1998-12-02 Nestlé Produkte AG Procédé de traitement d'une matiére première lactosérique
AU771754B2 (en) 1999-06-29 2004-04-01 New Zealand Milk Institute Limited, The Prophylactic dietary supplement based on milk
EP1420811A2 (en) * 2001-04-10 2004-05-26 Societe Des Produits Nestle S.A. Method and composition for prophylaxis of diabetes
DE602004021172D1 (de) 2003-02-10 2009-07-02 Univ London Säuglingsnährsystem
CA2538507A1 (en) 2003-08-30 2005-03-10 Nestec S.A. Acid soluble proteins from micellar casein
EA200601575A1 (ru) 2004-03-01 2007-06-29 Пептера Фармасьютикалс Лтд. Казеиновые пептиды и их терапевтическое применение
CN101212911B (zh) 2005-07-01 2012-12-05 努特里希亚公司 含水解的蛋白质的婴儿营养品
CN101299934B (zh) 2005-10-05 2012-08-08 雀巢技术公司 用于促进追赶生长的营养制剂
WO2008054192A1 (en) 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
PL1981358T3 (pl) 2006-01-31 2011-04-29 Nestec Sa Kompozycja żywieniowa dla noworodków z niską wagą urodzeniową
DE102006052560B4 (de) 2006-11-06 2010-01-21 Humana Milchunion Eg Anti-diabetogene Calcium-Peptid-Zusammensetzung
EP1932437A1 (en) * 2006-12-15 2008-06-18 Nestec S.A. Infant formula

Also Published As

Publication number Publication date
MY183275A (en) 2021-02-18
EP2413952A1 (en) 2012-02-08
WO2010112430A1 (en) 2010-10-07
SG174355A1 (en) 2011-10-28
US20120021977A1 (en) 2012-01-26
MX2011010454A (es) 2012-01-25
CA2755860A1 (en) 2010-10-07
EP2413952B2 (en) 2019-10-02
RU2011144581A (ru) 2013-05-10
EP2413952B1 (en) 2016-03-23
CL2011002465A1 (es) 2012-03-23
PL2413952T3 (pl) 2017-08-31
ES2570461T5 (es) 2020-04-03
CN102378632A (zh) 2012-03-14
AU2010230283A1 (en) 2011-10-13
AU2010230283B2 (en) 2015-02-05
TW201039754A (en) 2010-11-16
BRPI1014065A2 (pt) 2016-04-12
US8846612B2 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
ES2570461T3 (es) Mejora en la promoción del crecimiento compensatorio sano
MX2016006577A (es) Uso de composiciones nutritivas que tienen una cantidad baja de proteina.
BR112015014510A2 (pt) agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
CY1122060T1 (el) Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων
ECSP19046893A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
CL2013000594A1 (es) Composicion que comprende hidrolizado de proteina en base lactea que proviene del tratamiento de una solucion de un material proteinaceo de base lactea con al menos una endopeptidasa tipo tripsina, y una endopeptidasa tipo quimotripsina; uso de dicha composicion como fórmula infantil o complemento alimenticio para inducción de tolerancia oral en infantes o pacientes que lo necesitan, o para reducir el riesgo de alergias.
CY1119987T1 (el) Παραγωγα εξενδινης-4 ως διττοι αγωνιστες glp1/γλυκαγονης
CY1115649T1 (el) Σκευασματα ινσουλινων μακρας-δρασης
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
BR112014009225A2 (pt) uso de micelas de proteína de soro de leite para crianças pequenas em risco de obesidade ou diabetes
BR112014004726A2 (pt) combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
AR053803A1 (es) Uso de acido pinolenico
PH12016500774A1 (en) Nutritional composition for use in reducing metabolic stress in infants, decreasing gut permeability and approximating growth rate of breast-fed infants
UA115811C2 (uk) Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування
CL2018001826A1 (es) Composiciones que comprenden 2fl y lnnt para controlar la ingesta de alimento y el crecimiento en infantes o niños pequeños
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
PH12015502127A1 (en) Low calorie infant formula containing beta-hydroxy-beta-methylbutyric acid
PH12016500766A1 (en) Age-tailored nutritional compositions with a varying protein content
AR084495A1 (es) Dispositivo para dormir
PE20141826A1 (es) Uso de composiciones nutricionales que incluyen lactoferrina en apoyo a la resistencia a enfermedades y condiciones
PE20151498A1 (es) Composicion nutricional para promover la saciedad
CL2011001734A1 (es) Composición nutricional para infantes que comprende una fuente de proteína, una fuente de lípido y una fuente de carbohidrato, donde la fuente de lípido comprende ácido linoléico y ácido alfa-linolénico
CL2015002299A1 (es) Composición alimenticia y uso de la misma para balance proteico
MX384123B (es) Nutrición infantil para el mejoramiento en la sensibilidad a la insulina más adelante en la vida.
BRPI0812026A2 (pt) mutantes de vegf-d e seu uso